MRTX849 for Colorectal Cancer
Study Summary
This trial is testing a new drug, MRTX849, to see if it is better than chemotherapy at treating colorectal cancer that has a KRAS G12C mutation.
- Colorectal Cancer
- Metastatic Colorectal Cancer (CRC)
- Colorectal Carcinoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 5 Secondary · Reporting Duration: 30 months
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
mFOLFOX6 or FOLFIRI
1 of 2
MRTX849 + Cetuximab
1 of 2
Active Control
Experimental Treatment
420 Total Participants · 2 Treatment Groups
Primary Treatment: MRTX849 · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 22nd, 2021
Last Reviewed: November 1st, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Alabama | 100.0% |
How old are they?
| 65+ | 100.0% |
What site did they apply to?
| SCRI - Tennessee Oncology - Chattanooga - Memorial Plaza | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |